Qiagen N.V. Stock Forecast
NYSE: QGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 45.38 -0.02%
QGEN analyst consensus
Consensus (16 analysts)
buy
Avg. price target
$47.27+4.16%
- Strong buy 5
- Buy 4
- Hold 7
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 16 Wall Street analysts covering Qiagen N.V. (2026-10-07), 9 rate the stock a buy or strong buy, 7 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $47.27, with a high estimate of $55.00 and a low estimate of $40.00. The average target implies upside of 4.2% from the current price of $45.38.
The spread between the highest and lowest targets is 37.5%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for QGEN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 5 | 31% |
| Buy | 4 | 25% |
| Hold | 7 | 44% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $40.00 | -11.86% |
| Average target | $47.27 | +4.16% |
| High target | $55.00 | +21.20% |